immuno-oncology

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

News

window into laboratory with scientist hard at work

Autolus bags FDA approval for leukaemia cell therapy

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL).

News

Alligator pancreatic cancer drug 'nearly doubles' survival

Alligator Bioscience has reported updated results with its CD40 agonist mitazalimab as a first-line treatment for advanced pancreatic cancer, a disease with few treatment options.<

News

vaccine vial held by hands in surgical green gloves

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-sta

News

Transgene cervical cancer shot misses the mark in phase 2

Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study

News

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

BioNTech buys Biotheus and its Keytruda rival for $950m

Autolus bags FDA approval for leukaemia cell therapy

Alligator pancreatic cancer drug 'nearly doubles' survival

MSD, Moderna start phase 3 adjuvant lung cancer trial

Transgene cervical cancer shot misses the mark in phase 2

MSD hits a hurdle with its LAG-3 programme

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

immuno-oncology

Editor's Picks